



# French Guiana, France

Region of the Americas




## I. Epidemiological profile

Population (UN)	2015	%	Parasites and vectors
High transmission (> 1 case per 1000 population)	230,000	86	Plasmodium species: <i>P. falciparum</i> (47%), <i>P. vivax</i> (53%)
Low transmission (0-1 cases per 1000 population)	39,000	15	Major anopheles species: <i>An. darlingi</i>
Malaria-free (0 cases)	0	-	Reported confirmed cases (health facility): 434 Estimated cases: 730 [470 ; 1,500]
Total	269,000	-	Confirmed cases at community level: - Reported deaths: 0 Estimated deaths: <10

## II. Intervention policies and strategies


Intervention	Policies/strategies	Yes/No	Adopted	Antimalarial treatment policy	Medicine	Year adopted					
ITN	ITNs/ LLINs distributed free of charge	Yes	2012	First-line treatment of unconfirmed malaria	-	-					
	ITNs/ LLINs distributed to all age groups	Yes	2012	First-line treatment of <i>P. falciparum</i>	AL	-					
IRS	IRS is recommended	Yes	-	Treatment failure of <i>P. falciparum</i>	AQ+PG	-					
	DDT is authorized for IRS	No	-	Treatment of severe malaria	AS; AL	-					
Larval control	Use of larval control recommended	Yes	-	Treatment of <i>P. vivax</i>	CQ+PQ	-					
IPT	IPT used to prevent malaria during pregnancy	N/A	-	Dosage of Primaquine for radical treatment of <i>P. vivax</i>	-	-					
Diagnosis	Patients of all ages should receive diagnostic test	Yes	-	Type pf RDT used	P.f + all species (Combo)						
	Malaria diagnosis is free of charge in the public sector	No	-								
Treatment	ACT is free of charge for all ages in public sector	Yes	-	<b>Therapeutic efficacy tests (clinical and parasitological failure, %)</b>							
	The sale of oral artemisinin-based monotherapies (oAMTs)	Never allowed	-	Medicine	Year	Min	Median	Max	Follow-up	No of studies	Species
	Single dose of primaquine is used as gametocidal medicine for <i>P. falciparum</i>	No	-								
	Primaquine is used for radical treatment of <i>P. vivax</i>	Yes	-								
	G6PD test is a requirement before treatment with primaquine	Yes	-								
	Directly observed treatment with primaquine is undertaken	No	-								
	System for monitoring adverse reactions to antimalarials exists	Yes	-								
Surveillance	ACD for case investigation (reactive)	No	-	<b>Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)</b>							
	ACD of febrile cases at community level (pro-active)	No	-	Year	Pyrethroid	DDT	Carbamate	Organophosphate	Species/complex tested		
	Mass screening is undertaken	No	-	2010-2014							
	Uncomplicated <i>P. falciparum</i> cases routinely admitted	Yes	-								
	Uncomplicated <i>P. vivax</i> cases routinely admitted	Yes	-								
	Foci and case investigation undertaken	-	-								
Case reporting from private sector is mandatory	-	-									

## III. Financing




## Government expenditure by intervention in 2015


## IV. Coverage




## Cases tested and treated in public sector




## V. Impact



## Test positivity



## Confirmed malaria cases per 1000 and ABER



## Malaria admissions and deaths

